



# Oncoclínicas

---

## 1Q26 Earnings Call Presentation

May 15<sup>th</sup>, 2026

ONCOCLINICAS & CO

# LEGAL NOTICE


---

This presentation is updated until the date hereof and is subject to change without notice, and the Company undertakes no obligation to update or revise the information presented as a result of new information and / or future developments. This presentation may contain information and the Company's expectations about future events or results that do not describe historical facts but reflect the opinion of the Company's Management. The information contained herein is based on various assumptions and factors of an operational, economic and market nature and should not be construed as legal or tax advice or a suggestion to invest in the Company's shares, nor should it serve as the basis for any related contract or commitment. Under no circumstances shall the Company be liable to third parties (including investors) for any investment decision taken based on the information presented herein, or for any damages resulting therefrom. This presentation and its contents are proprietary information of the Company and may not be reproduced or circulated, in part and / or in whole, without the Company's prior, express, written consent.


## DROP IN PROCEDURES REFLECTS THE IMPACT OF THE DYNAMICS OF DRUG SUPPLY DURING THE QUARTER

A 4.8% increase in the average ticket price compared to the last quarter (1Q26 vs. 4Q25) reflects higher quality in commercial negotiations.

Procedures (in Thousands) and Average Ticket (R\$) per Quarter



Procedures (in Thousands) and Average Ticket (R\$) LTM




## GROSS REVENUE REACHED R\$ 6.1 BILLION IN LTM 1Q26

A sequential increase of 1.2%, even considering the impact of drug supply dynamics during the quarter.


### Gross Revenue (Quarterly)

R\$ million



### Gross Revenue Annual

R\$ million




## NET REVENUE OF R\$ 5.4 BILLION IN LTM 1Q26

Indicator impacted by the accounting provision adjustment for PCLD<sup>1</sup> during the quarter.


### Net Revenue (Quarterly)

R\$ million



### Net Revenue Annual

R\$ million




1- Provision for Glosas (Disallowances) and Doubtful Accounts.

## PCLD<sup>1</sup> IMPACTED BY THE ACCOUNTING PROVISION ADJUSTMENT MADE DURING THE QUARTER

The average LTM for Q1 2026 was slightly higher than the Company's historical average due to provisions made during the quarter.

Evolution of PCLD Provisions<sup>1</sup> as a % of Gross Revenue per Quarter




Average LTM 1Q25: 2.6%  
Average LTM 1Q26: 5.9%

1- Provision for Disallowances and Doubtfull Accounts.

## GROSS CASH MARGIN: 31.3% IN LTM 1Q26, STABLE COMPARED TO THE SAME PERIOD OF THE PREVIOUS YEAR


### Cash Gross Profit and Cash Margin (Quarterly)

R\$ million



### Cash Gross Profit and Cash Margin LTM

R\$ million




Cash Gross Profit
  Cash Gross Profit Ex-Hospitals (%)
  Cash Gross Margin (%)
  Cash Gross Margin - Ex-Hospitals (%)

## OPERATING EXPENSES IMPACTED BY ACCOUNTING ADJUSTMENTS

Approximate impact of R\$ Impact of approximately R\$ 148 million related to the risk of credit loss in relation to Unimed Leste Fluminense and adjustment of the provisioning policy for doubtful accounts.

### Cash Operating Expenses<sup>1</sup> (and % of Gross Revenue)

R\$ million




1- Operating Expenses before depreciation and amortization

**ADJUSTED EBITDA<sup>1</sup> OF R\$ 627.9 MILLION IN LTM 1Q26, AN INDICATOR IMPACTED BY THE DYNAMICS OF DRUG SUPPLY DURING THE QUARTER AND PCLD. ON A RECURRING BASEIS, ADJUSTED EBITDA WAS R\$ 110.2 MILLION.**


**Adjusted EBITDA<sup>1</sup> and Margin (Quartely)**

R\$ million



**Adjusted EBITDA<sup>1</sup> and Margin LTM**


R\$ million




1- Excluding non-recurring items and hospitals

## NET INCOME IMPACTED BY LOWER OPERATING LEVERAGE DURING THE QUARTER AND ACCOUNTING ADJUSTMENTS

### Adjusted Net Income Ex-Hospitals<sup>1</sup> (Quarterly) (R\$ million)



### Adjusted Net Income Ex-Hospitals<sup>1</sup> LTM (R\$ million)



1- Excluding non-cash charge related to fair value of long-term equity incentive plan (LTIP) and non cash non recurring charges.

## WORKING CAPITAL CYCLE REFLECTING RENEGOTIATION WITH THE COMPANY'S MAIN SUPPLIER

### Average Working Capital Days by Quarter (90 Days Base Calculation)

In days


	1Q25	2Q25	3Q25	4Q25	1Q26
Receivables (1)	108	96	88	93	90
Inventory (2)	16	20	16	19	13
Payables (3)	83	75	79	111	111
Net WK Days <sup>1</sup>	40	40	25	1	(9)

<sup>1</sup> – Calculation: (A) + (B) - (C)

## DETAILED QoQ CASH POSITION RECONCILIATION IN SEQUENTIAL COMPARISON

### QoQ Cash Position Reconciliation


R\$ million



## NET DEBT IMPACTED BY LOWER CASH POSITION DURING THE PERIOD

Net Debt (Financial Debt + Sellers Finance - Cash) / Annual Adjusted EBITDA

R\$ million



# THANK YOU

---

**Contact IR**



**Website:** [ri.grupooncclinicas.com](http://ri.grupooncclinicas.com)



**Email:** [ri@oncclinicas.com](mailto:ri@oncclinicas.com)



**ONCOCLINICAS&CO**